| ATCC 51860| ATCC:51866 [[Corynebacterium seminale]]| CCUG 35055| CCUG:34780 [[Corynebacterium seminale]]| CCUG:34888 [[Corynebacterium seminale]]| CIP 104577| CIP:104297 [[Corynebacterium seminale]]| Corynebacterium glucuronolyticum| Corynebacterium glucuronolyticum Funke et al. 1995| Corynebacterium seminale| Corynebacterium seminale Riegel et al. 1996| DMMZ 838| DSM 44120| DSM 44288 [[Corynebacterium seminale]]| JCM 11612| JCM:10394 [[Corynebacterium seminale]]| LMG 19047| LMG:19047| strain IBS B12915 [[Corynebacterium seminale]]
Co-infection with HBV: HDV can infect individuals who are already infected with HBV or can coinfect individuals concurrently with HBV. Coinfection with HDV and HBV can lead to a more severe form of acute hepatitis compared to HBV infection alone.
Superinfection: HDV can also cause superinfection in individuals who are already chronically infected with HBV. Superinfection with HDV in individuals with chronic HBV infection can lead to more severe liver disease, including fulminant hepatitis, liver cirrhosis, and hepatocellular carcinoma (liver cancer).
Chronic Hepatitis: Chronic infection with HDV can lead to chronic hepatitis delta, which can progress to cirrhosis and end-stage liver disease. Chronic hepatitis delta is associated with a higher risk of liver-related morbidity and mortality compared to chronic HBV infection alone.
Transmission: HDV is transmitted primarily through percutaneous exposure to infected blood or other body fluids. It can also be transmitted vertically from mother to child during childbirth and through sexual contact.
Global Impact: HDV infection is a significant public health concern globally, particularly in regions where HBV infection is endemic. It is estimated that there are approximately 15-20 million individuals worldwide who are chronically infected with HDV.
Prevention and Treatment: Prevention of HDV infection involves vaccination against HBV, as HDV requires HBV for its replication. Treatment options for chronic hepatitis delta are limited and often less effective compared to treatment for chronic HBV infection. Current treatment options include interferon-based therapies, but they are associated with limited efficacy and significant side effects. Research into new treatment strategies for hepatitis delta is ongoing.
The above data is from 1000 Healthy Individuals done using Shotgun(10 Millions reads) provide courtesy of Precision Biome.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
![]() |
NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | Average | Median | Minimum | Maximum | Std.Dev. | Skew | 25 - 75 Percentile | 5 - 95 Percentile | Lab Ranges | Box-Plot-Whiskers | Harmonic Mean | Geometric Mean | Obs. |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BiomeSight | 0.0364 | 0.0124 | 0.003 | 0.001 | 0.241 | 0.0289 | 0.9751 | 0.002 - 0.011 | 0.001 - 0.0459 | -0.044 - 0.0687 | -0.0115 - 0.0245 | 0.0027 | 0.0047 | 135 |
Thorne | 0.037 | 0.0004 | 0.0002 | 0.0001 | 0.0012 | 0.0004 | 1.3175 | 0.0002 - 0.0004 | 0.0001 - 0.001 | -0.0004 - 0.0011 | -0.0002 - 0.0008 | 0.0002 | 0.0003 | 7 |
Thryve | 0.0202 | 0.0289 | 0.0042 | 0.001 | 0.3855 | 0.078 | 0.9511 | 0.0021 - 0.0198 | 0.0011 - 0.096 | -0.1232 - 0.1811 | -0.0244 - 0.0464 | 0.0033 | 0.0066 | 25 |
uBiome | 0.0342 | 0.0234 | 0.0107 | 0.0023 | 0.1762 | 0.0437 | 0.8715 | 0.0047 - 0.0198 | 0.0025 - 0.1265 | -0.0619 - 0.1087 | -0.0179 - 0.0424 | 0.0068 | 0.0107 | 27 |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
PrecisionBiome | 1.1231148164370097E-05 | 9.713770123198628E-05 | 0 | 0 |
|
And display level must be raised above public.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]